SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is currently under intense scrutiny as it approaches its earnings release, with investors weighing the company's 'Win Now' turnaround strategy against ongoing concerns regarding market share, tariff-driven costs, and performance in the China market. While some in the community see the current multi-year lows as a compelling buying opportunity, others remain skeptical, citing continued bearish price action and poor sentiment as indicators that the stock may face further downside before a meaningful recovery.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending as investors gear up for the company's long-awaited 10-K filing and Q4 earnings call, with community sentiment fueled by debt reduction progress and the strong performance of key holdings like Applied Digital and BW. The community is actively debating the potential for a valuation re-rating and a short squeeze, balancing caution over compliance deadlines against bullish conviction in the firm's turnaround strategy.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is seeing a significant boost in sentiment following the official commercial launch of YARTEMLEA, as investors are actively tracking shipping updates and initial hospital adoption to validate the revenue potential of the drug. Community discourse is heavily focused on the company's ability to maintain a strong cash position while managing short interest, with many hoping that the confirmation of sales will finally force a break from recent price consolidation and attract institutional capital.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware is experiencing significant volatility driven by concerns over new import tariffs, leading to a sharp sell-off as investors weigh the impact on the company's heavily China-dependent supply chain. While some traders are betting on a short squeeze or a potential rebound if tariffs are eased, the community remains deeply divided, with many debating whether the stock's recent decline represents an oversold buying opportunity or a deeper fundamental issue.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is experiencing heightened volatility and intense social media debate, driven by skepticism over its aggressive debt-financed Bitcoin accumulation strategy amidst cooling market conditions. The community remains deeply polarized, with bulls viewing recent price dips as a long-term loading opportunity while bears increasingly voice concerns regarding potential dilution, liquidity risks, and the stock's sensitivity to broader macroeconomic pressures.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is capturing intense investor attention as participants digest new Phase 3 data for sonelokimab, while retail traders and institutional interests remain fixated on the potential for a high-value acquisition by major pharmaceutical players. The community is actively debating the drug's 'best-in-class' potential, with discussions heavily focused on clinical trial metrics and the persistent tension between long-term bullish sentiment and ongoing concerns regarding market manipulation.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing heightened volatility and intense social media discussion as retail investors bet on a potential short squeeze, citing high short interest and technical support levels. Despite broader market uncertainty, the community remains divided between those accumulating shares at perceived bargain prices and bears skeptical of the company's profitability and recent price performance.

"What's Updog?" is a Community Led token.

UpDog

UpDog is generating significant buzz as its community actively rallies behind the ticker to push for mass adoption and increased visibility across social channels. Investors are focused on leveraging the project's long-standing presence and unique engagement style to drive further momentum for the token.

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals is trending after the FDA approved EMPAVELI for the treatment of rare kidney diseases, marking a significant milestone that investors hope will catalyze long-term growth. The community is actively discussing whether this label expansion de-risks the company as a potential buyout target while closely monitoring upcoming earnings for signs of sustained commercial execution.

Dave & Buster's Entertainment, Inc. engages in the ownership and operation of entertainment and dining venues under the name Dave & Buster's. It offers a full menu of entrées and appetizers, a selection of alcoholic and non-alcoholic beverages, and an assortment of entertainment attractions centered around playing games and watching live sports and other televised events. The company was founded by David O. Corriveau and James W. Corley in 1982 and is headquartered in Coppell, TX.

Dave & Buster`s Entertainment Inc

Dave & Buster's Entertainment

Dave & Buster's is currently a focal point for retail traders who are closely monitoring its high short interest and institutional activity as a potential catalyst for a squeeze. While the community remains divided over the company's long-term business model and recent financial performance, the stock's recent volatility has intensified discussions regarding its technical breakout levels and speculative upside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Best Mid Cap Stocks To Watch Today - March 31st

ProShares UltraPro Short QQQ, Apellis Pharmaceuticals, Centessa Pharmaceuticals, Applied Optoelectronics, and Direxion Daily TSLA Bull 2X Shares are the five Mid Cap stocks to watch today, according to MarketBeat's stock screener tool. Mid-cap stocks are shares of companies with market capitalizati...

Noteworthy Tuesday Option Activity: APLS, AMTM, EXP

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Apellis Pharmaceuticals Inc (Symbol: APLS), where a total volume of 23,358 contracts has been traded thus far today, a contract volume which is representative of...

Pharmaceutical Stocks To Watch Today - March 31st

Apellis Pharmaceuticals, Centessa Pharmaceuticals, Eli Lilly and Company, AbbVie, Pfizer, Abbott Laboratories, and Novo Nordisk A/S are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that r...

Medical Stocks To Add to Your Watchlist - March 31st

Apellis Pharmaceuticals, Centessa Pharmaceuticals, Eli Lilly and Company, UnitedHealth Group, Boston Scientific, AbbVie, and Pfizer are the seven Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of companies involved in healthcare including p...

Apellis Pharmaceuticals (NASDAQ:APLS) Receives "Hold" Rating from Needham & Company LLC

Needham & Company LLC reissued a "hold" rating on shares of Apellis Pharmaceuticals in a research note on Tuesday...

Shareholder Alert: The Ademi Firm investigates whether Apellis Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders

Shareholder Alert: The Ademi Firm investigates whether Apellis Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders Shareholder Alert: The Ademi Firm investigates whether Apellis...

Are APLS, CNTA, BIRD Obtaining Fair Deals for their Shareholders?

Are APLS, CNTA, BIRD Obtaining Fair Deals for their Shareholders? Are APLS, CNTA, BIRD Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, March 31, 2026 Insiders may stand to receive...

Apellis Pharmaceuticals (NASDAQ:APLS) Sets New 1-Year High - Here's Why

Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 1-Year High - Time to Buy...

Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave...

Futures Jump On Hopes Of War De-escalation, Korea Enters Bear Market On Memory Rout

Futures Jump On Hopes Of War De-escalation, Korea Enters Bear Market On Memory Rout

 Futures are higher on a WSJ report that Trump is considering exiting the middle east conflict even if the Strait of Hormuz is not reopened; but the market is deciding whether this is a genuine intent to...

iShares Dynamic Equity Active ETF ($BDYN)

Grayscale Bitcoin Trust ETF ($GBTC)

Destiny Tech100 Inc ($DXYZ)

Global X Defense Tech ETF ($SHLD)

The Modern Portfolio Builder. This award honors the fund that makes long-term investing easier, cheaper, or more effective for people who want to "set it and forget it."

Stocktwits

Stocktwits Polls

Biogen has announced a definitive $5.6 billion agreement to acquire the company for $41 per share in cash plus CVRs.

Market participants are celebrating the massive gains after shorts were caught off guard by the buyout announcement.

Traders are actively scouting for the next acquisition target in the biotech sector, citing recent market consolidation.

Investors are dissecting the deal structure and debating the value of contingent value rights versus current market price.

APLS
Apellis Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest APLS News

APLSApellis Pharmaceuticals Inc